Is Portola Pharmaceuticals Inc. (NASDAQ:PTLA) worth grabbing?


Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) stock had a weekly volatility of 4.12% and a monthly volatility of 3.83%. Portola Pharmaceuticals, Inc. PTLA shares float stands at 55.54M.

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Minimum.

Recently, Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) reported that Portola Pharmaceuticals, Inc. quarterly Return on Assets is -69.80%, while quarterly Return on Equity was -108.10% and quarterly Return on Investment was -112.00%.

The firm’s Total Debt/Equity stood at 0.61 while Long Term Debt/Equity was 0.61.

The firm’s stock 50-Day High is $-12.54% and a 50-Day Low of $6.13%. 20-Day Simple Moving Average was $-4.39% while 50-Day SMA was $-3.59%.

The firm announced EPS of $-4.35. This shows an EPS growth quarter over last quarter was 36.10%%. EPS for the year was $-9.30%. For the last 5-year, the stock has recorded EPS growth for imminent year is projected to be 37.20%.

The firm’s monthly average volume for the reported quarter was 774.99K and 774.99K for the full fiscal year. The relative volume was 0.83 for the quarter and 0.83 for the full fiscal year.

The stock’s 50-Day High in the last quarter was $-12.54% while the 50-Day Low was $6.13%. In the last fiscal year, the stock hit a 52-Week High of $-12.54% and a 52-Week Low of $138.39%.

The firm’s insider ownership was 0.10% and institutional ownership was 91.70%. Total institutional transactions amounted to -0.22%. Sales growth QoQ was -38.60%.

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) announced that preclinical and clinical data on cerdulatinib in relapsed/refractory b-cell malignancies will be presented at the European Hematology Association (EHA), which is taking place from June 22-25 in Madrid, Spain.